



Leadership Team

Mike Luther, PhD, MBA
Chief Executive Officer

Matt Kostura, PhD
Chief Scientific Officer

Michael Stocum, MS
Chief Business Officer

Alan Cooper, PhD
Head of Chemistry

Andy Anantha, PhD
Head of CMC

Scientific Advisory Board

Briggs Morrison, MD
CEO, Syndax, Inc.

Mike Patane, PhD
President, Mitobridge/Astellas

Jedd Levine, MD, MBA
EVP, Oncology Partners

Josh Rabinowitz, MD, PhD
Princeton University

Rainer Fuchs, PhD
Former CIO Harvard Medical School; Biogen & GSK R&D

Mark Manfredi, PhD
CEO, Kyn Therapeutics

David Weinstock, MD
Dana-Farber Cancer Institute

Industry

Pharmaceuticals, Oncology, Cancer metabolism

Financing To date

Syndicate of Private Investors

Company Founding

August 2015 Delaware LLC

Contact Information

BANTAM PHARMACEUTICAL
646-598-4823
www.bantampharma.com
info@bantampharma.com

Highlights

- Bantam is an oncology-focused biotech company developing first-in-class small molecules to treat diffuse large B-cell lymphomas (DLBCL) plus other lymphomas and solid tumors based on a biomarker-driven precision medicine development strategy.
- Clinical candidate, BTM-3566 is an orally available small molecule with a novel mechanism of action (MoA) through modulation of a mitochondrial pathway.
- Demonstrated Proof-of-Concept (PoC) with *durable, complete tumor regressions* in B-cell lymphoma xenograft and PDX studies as single agent, once daily oral dosing.
- Safety pharmacology and dose related finding studies complete.
- Extensive IP estate with patent protection through 2039.
- FDA IND (Investigational New Drug) Application to be filed in late 2020.
- Strong leadership team with scientific expertise in oncology drug development.
- **Company is raising \$20M for IND enabling studies and completion of Phase 1a/1b clinical PoC by 2022. Investment enables value inflection points for potential exit.**

THERAPEUTIC ASSET: Orally available small molecule clinical candidate, BTM-3566, and pipeline of first-in-class proprietary compounds that impact a novel cancer mitochondrial metabolism pathway. This unique MoA is distinct from known targeted therapeutics and characterized by modulation of the HRI-eIF2alpha-ATF4 stress pathway. Bantam is targeting cancers with unmet clinical need initially in refractory and recurrent DLBCL, then expanding to biomarker selected patients with lymphoid cancers and solid tumors.

MARKET OPPORTUNITY: Successful development and commercialization of Bantam compounds could positively impact the lives of >150,000 patients/year in the US alone and address a large US and global market. Total potential annual market for lymphoma and selected solid tumor therapies is estimated to be >\$10 Billion/year.

Bantam Pharmaceutical is now expanding its base of investors and partners as it rapidly advances its pipeline toward clinical PoC studies.

EXPERIENCED TEAM: The Bantam leadership team has a proven track record in oncology biopharma drug discovery and development. Bantam’s advisory board is comprised of prominent industry leaders with drug development and executive leadership roles with successful companies spanning start-up through global pharma.

INTELLECTUAL PROPERTY: Bantam owns an intellectual property estate that covers the compounds, chemical space, and their broad clinical utility. Bantam has recently filed patent applications that feature additional claims related to mechanism and routes of administration as well as chemical development. The IP portfolio will support Bantam’s pipeline and any derivative products through at least 2039.

NEAR TERM MILESTONES AND CLINICAL PLAN: Bantam is rapidly progressing **BTM-3566** into the clinic and is seeking partners and funding to complete IND-enabling activities, manufacturing to support clinical trials, as well as the PoC clinical studies.

Key Milestones for BTM-3566	
Clinical Candidate Selection	Completed
IND-enabling studies & CMC Scale-up	In Progress
File IND	Q4 2020
Initiate Phase 1 studies	Q1 2021